NeOnc Technologies Holdings closed at $3.17 on Nov 4, up 3.26%, 73.2% below its 52-week closing high. Volume of 53.3K shares was 0.40× its 20-day average (below normal).
Split-adjusted performance: +6.0% over one month, -40.3% over six months, -68.9% over one year.
Short interest was 876.7K shares at the Oct 15 settlement, up 15.7% from the prior report (8.2% of float, 5.3 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NTHINeOnc Technologies Holdings | $3.17 | +3.26% | −40.3% | — | — | — | $91.3M | |
| PLYXPolaryx Therapeutics | $1.80 | +4.05% | −52.6% | — | — | — | $89.7M | Compare |
| GNLXGenelux | $1.96 | +2.08% | −31.7% | — | — | — | $88.7M | Compare |
| PDSBPDS Biotechnology | $1.30 | −7.80% | +22.6% | — | — | — | $94.2M | Compare |
| VTVTvTv Therapeutics | $24.03 | +2.04% | −24.1% | — | — | — | $95.0M | Compare |
| TNXPTonix Pharmaceuticals Holding | $5.11 | −1.54% | −65.2% | +577.9% | −299.4% | — | $87.6M | Compare |
| MISTMilestone Pharmaceuticals | $0.7725 | +1.74% | −60.8% | — | −5118.8% | — | $96.2M | Compare |
| RLYBRallybio | $15.90 | +0.25% | +9.2% | −100.0% | — | 3.2 | $85.6M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
